Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334174 | 0.98 | HRH3 (0.58) | HRH3KCNH2CYP2C9CYP3A4NFE2L2 | |
| SCHEMBL5556221 | 0.91 | HRH3 (0.63) | HRH3KCNH2CYP2C9CYP3A4NFE2L2 | |
| SCHEMBL9808038 | 0.87 | HRH3 (0.71) | HRH3KCNH2CYP2C9CYP3A4NFE2L2 | |
| SCHEMBL26041153 | 0.83 | SLC18A3 (0.47) | HRH3KCNH2CYP2C9CYP3A4 | |
| SCHEMBL8683784 | 0.82 | HRH3 (0.60) | HRH3KCNH2CYP2C9CYP3A4NFE2L2 | |
| SCHEMBL10798982 | 0.82 | HRH3 (0.60) | HRH3KCNH2CYP2C9CYP3A4MEN1 | |
| SCHEMBL4906564 | 0.82 | HRH3 (0.60) | HRH3KCNH2CYP2C9CYP3A4NFE2L2 | |
| SCHEMBL8682954 | 0.82 | HRH3 (0.60) | HRH3KCNH2CYP2C9CYP3A4NFE2L2 | |
| SCHEMBL4333330 | 0.82 | HRH3 (0.60) | HRH3KCNH2CYP2C9CYP3A4NFE2L2 | |
| SCHEMBL14318440 | 0.82 | HRH3 (0.60) | HRH3KCNH2CYP2C9CYP3A4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7371777-B2 | Cyclic compound and PPAR agonist | EISAI CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-7253178-B2 | Carboxylic acids | EISAI CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253178-B2 | Carboxylic acids | EISAI CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253178-B2 | Carboxylic acids | EISAI CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20050014833-A1 | Cyclic compound and ppar agonist | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1452521-A1 | CYCLIC COMPOUND AND PPAR AGONIST | Eisai Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-20040116708-A1 | Insulin sensitizers; antidiabetic agents, antiinflammatory agents; inflammatory bowel disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1375484-A1 | CARBOXYLIC ACIDS | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-4077962-A | WATER INSOLUBLE, GREEN-YELLOW, SYNTHETIC FIBERS | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014833-A1 | Cyclic compound and ppar agonist | PPARA, PPARG, PPARD | HRH3 1085/4885KCNH2 1437/4885CYP2C9 971/4885 |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | HRH3 955/4885KCNH2 2126/4885CYP2C9 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.